Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- Check2 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-status notice and the earlier Revision: v3.4.1.SummaryDifference0.4%

- Check9 days agoChange DetectedAdded a government-funding notice about site operations. Updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check16 days agoChange DetectedGlossary feature added to the page. Metadata labels updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision version bumped from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check30 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4, indicating a minor site update with no changes to the study details, enrollment, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedDifference0.2%

- Check74 days agoChange DetectedRevision label updated to v3.3.2; no study content or functionality changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.